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Background: The frequent genetic functional variant 681 G>A (*2) of cytochrome P450 2C19 (CYP2C19) is an important contributor to the wide 
variability between individuals of the antiplatelet effect of clopidogrel. We wanted to investigate whether the CYP2C19*2 polymorphism affected 
long-term prognosis of Chinese patients who were treated with clopidogrel after percutaneous coronary intervention(PCI).
Methods: Between January 1,2008 and December 31,2009,267 Patients who received PCI and were exposed to clopidogrel treatment for almost 
12 months, were enrolled in Fu Wai Hospital and underwent CYP2C19*2 determination. Follow-up was 12 months. The primary endpoint was a 
composite of death, myocardial infarction, urgent coronary revascularisation and stent thrombosis.occurring during exposure to clopidogrel. .
Results: The patients were grouped CYP2C19*1/*1(n=130), CYP2C19*1/*2(n=111) and CYP2C19*2/*2(n=26) by genetype, and baseline 
characteristics were balanced among the three groups. Urgent coronary revascularization occurred more frequently in CYP2C19*2/*2 and 
CYP2C19*1/*2 than in CYP2C19*1/*1(3 vs 7 vs 2, P<0.05). There were no significant difference among three groups with myocardial 
infarction, stent thrombosis and death (P>0.05). The combined end points also occurred more frequently in CYP2C19*2/*2 and 
CYP2C19*1/*2 than in CYP2C19*1/*1(4 vs 7 vs 3, P<0.05). During the following time, cumulative survival of CYP2C19*2/*2 was lower than 
CYP2C19*1/*1(HR=5.65[95%CI:1.63-19.49],P=0.006). Comparing Cumulative survival of CYP2C19*1/*2 with CYP2C19*1/*1, there were no 
significant difference (HR=1.69[95%CI:0.53-5.36],P=0.376).
Conclusions: CYP2C19*2 genetic variant is a major determinant of prognosis in chinese patients with cardiac heart disease(CHD) who are 
receiving clopidogrel treatment after PCI. CYP2C19*2/*2(homozygous) brings a worse influence than CYP2C19*1/*2(heterozygous).
